Clinical Trials Directory

Trials / Unknown

UnknownNCT02637479

Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery

Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery: A Multicenter, Prospective, Randomized Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Assistance Publique Hopitaux De Marseille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

80% of palliative care cancer patients suffer from severe pain. The management of these pain improves the quality of life of these patients. The management of opioid pain refractory to date remains a difficulty for caregivers. Hypophysectomy performed to try to control hormone-dependent neoplasia also help relieve pain associated with lesions secondary cancer. The surgical hypophysialis radio Gamma Knife ® was recently performed on a small number of patients. She would have the advantage of reducing the risk of complications compared to other techniques and achieve similar analgesic effect on diffuse, or mixed nociceptive pain associated with metastases on average in 2 days and would reduce or stop opiates most often responsible for side effects impairing the quality of life. The objective of this clinical trial, multicenter, prospective, randomized controlled is to evaluate the effectiveness of surgical hypophysialis radio for patients in palliative situations with refractory cancer pain in opioid level III. The type of pain "cancer pain" was done in order to optimize the recruitment and homogenization of the study population: patients cared for in palliative care units are mostly patients cancer (70-80%). This study is therefore part of a palliative setting and the results of this test can be extrapolated to other populations of palliative patients with refractory pain.

Conditions

Interventions

TypeNameDescription
DEVICEGammaKnife®
DEVICE18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)
DEVICEMRI

Timeline

Start date
2015-12-01
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2015-12-22
Last updated
2025-01-30

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02637479. Inclusion in this directory is not an endorsement.